Adding Erlotinib in HCC Fails to Improve Outcomes

Article

In a phase III trial, erlotinib performed no better than placebo when added to sorafenib in treatment-naive patients with advanced hepatocellular carcinoma.

Ball-and-stick model of erlotinib

Ball-and-stick model of erlotinib

Erlotinib performed no better than placebo when added to sorafenib in treatment-naive patients with advanced hepatocellular carcinoma (HCC) in a randomized phase III trial.

At present, sorafenib is the only approved agent for advanced, unresectable HCC, but the epidermal growth factor receptor (EGFR) pathway has been implicated in HCC pathogenesis. “EGFR activation may interfere with HCC response to sorafenib, suggesting that EGFR inhibition may enhance tumor response,” wrote study authors led by Andrew X. Zhu, MD, of Massachusetts General Hospital in Boston. Because of that possibility, the EGFR inhibitor erlotinib was considered as a possibility to improve outcomes in these patients.

The new study included 720 patients with advanced HCC and underlying Child-Pugh class A cirrhosis, all of whom were naive to systemic treatment. The study was a multinational, multicenter, randomized trial, with 362 patients receiving sorafenib and erlotinib and 358 receiving sorafenib and placebo. Results were published online ahead of print on December 29 in the Journal of Clinical Oncology.

The median overall survival was not significantly different between the two groups, at 9.5 months with erlotinib and 8.5 months with placebo; this yielded a hazard ratio (HR) of 0.929 (95% CI, 0.781-1.106; P = .408). Median time to progression was also similar at 3.2 months with erlotinib and 4 months without, for a HR of 1.135 (95% CI, 0.944-1.366; P = .18). No subgroups showed any significant differences with regard to overall survival.

The objective response rate trended higher in the erlotinib patients, at 6.6% vs 3.9% (P = .102), though the disease control rate was significantly higher in the placebo group, at 52.5% vs 43.9% (P = .021). Safety was similar in the two groups; treatment-emergent serious adverse events (AEs) occurred in 58% of erlotinib patients and in 54.6% of placebo patients, and drug-related serious AEs and rates of treatment withdrawal were also similar.

Treatment duration was shorter in the erlotinib group, at 2.8 months vs 4 months. The authors wrote that this suggests an association between treatment duration and disease control rate, the causality of this relationship could not be determined.

“The lack of synergistic or additive effect suggests that EGFR signaling may not be pivotal in advanced HCC,” the authors concluded. “Sorafenib remains the standard of care for first-line treatment of advanced HCC.”

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.